| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 09/27/2011 | US8026254 Therapeutic agents useful for treating pain |
| 09/27/2011 | US8026244 Thioxanthine derivatives and their use as inhibitors of MPO |
| 09/27/2011 | US8026218 Bifunctional analgesic compounds for opioid receptor agonists and neurokinin-1 receptor antagonists |
| 09/27/2011 | US8026217 Compositions and methods for treating neural anoxia and spreading depression |
| 09/27/2011 | US8026213 Methods for treating muscle diseases and disorders |
| 09/27/2011 | US8026209 Administering a diagnostic agent with a carrier conjugated to a targeting molecule that binds to a lipopolysaccharide-sensitive polypeptide, which is either up-regulated or down-regulated in ECs by exposure to LPS; delivery into the EC vascular barrier and/or across the EC vascular barrier |
| 09/27/2011 | US8026109 Hapten-carrier conjugates for treating and preventing nicotine addiction |
| 09/27/2011 | US8026072 Method of identifying compounds that bind BAFF-R |
| 09/27/2011 | US8025897 Ibuprofen composition |
| 09/27/2011 | CA2647206C N-carbamoylmethyl-4-(r)-phenyl-2-pyrrolidinone, method of its preparation and pharmaceutical use |
| 09/27/2011 | CA2615611C Indazole derivatives |
| 09/27/2011 | CA2530005C Use of buprenorphine for the treatment of drug dependence withdrawal in a pregnant woman |
| 09/27/2011 | CA2475930C 3-alkanoylamino-propionic acid derivatives used as inhibitors of integrin avss6 |
| 09/27/2011 | CA2473409C Phenoxy-piperidines for the treatment of diseases such as schizophrenia and depression |
| 09/27/2011 | CA2463999C Drug delivery system for conscious sedation |
| 09/27/2011 | CA2453486C The natural ligand for orphan g protein coupled receptor gpr86 and methods of use |
| 09/27/2011 | CA2447276C Non-human animal model of oligodendrocyte developmental disorder |
| 09/27/2011 | CA2440630C Metalloproteinase inhibitors |
| 09/27/2011 | CA2440042C Carboxamide derivatives as therapeutic agents |
| 09/27/2011 | CA2351015C Novel system for regulating transgene expression |
| 09/27/2011 | CA2336218C Neurotrophic factors |
| 09/27/2011 | CA2258728C Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase |
| 09/22/2011 | WO2011116356A2 Positive allosteric modulators of group ii mglurs |
| 09/22/2011 | WO2011116355A2 Benzoisothiazolones as inhibitors of phosphomannose isomerase |
| 09/22/2011 | WO2011116282A2 Nicotinic acetylcholine receptor agonists |
| 09/22/2011 | WO2011115938A1 Spiro-tetracyclic ring compounds as beta - secretase modulators |
| 09/22/2011 | WO2011115928A1 Amino -dihydrooxazine and amino - dihydrothiazine spiro compounds as beta - secretase modulators and their medical use |
| 09/22/2011 | WO2011115813A1 Lactam acetamides as calcium channel blockers |
| 09/22/2011 | WO2011115416A2 Sedum sarmentosum fraction for breaking down alcohol and providing hangover relief |
| 09/22/2011 | WO2011115183A1 Novel monocyclic pyrimidine derivative |
| 09/22/2011 | WO2011114260A1 Cerebrospinal fluid purification system |
| 09/22/2011 | WO2011114220A1 Neuro-protective effects of adelostemma gracillimum and its isolated compounds |
| 09/22/2011 | WO2011114184A1 Amides of heterocyclic compounds as trpa1 inhibitors |
| 09/22/2011 | WO2011113988A1 New derivatives of propargylamine having neuroprotective capacity for the treatment of alzheimer's and parkinson's diseases |
| 09/22/2011 | WO2011113578A1 New oxadiazole derivatives |
| 09/22/2011 | WO2011113363A1 Agomelatine hydrobromide hydrate and preparation thereof |
| 09/22/2011 | WO2011113362A1 Agomelatine hydrochloride hydrate and preparation thereof |
| 09/22/2011 | WO2011086007A8 Compositions comprising andrographis paniculata and ginkgo biloba extracts complexed with phospholipids |
| 09/22/2011 | WO2011084086A3 Hydrated pyrido(4,3-b)indole-based pharmaceutical composition for treating neurodegenerative diseases, method for producing same and pharmaceutical agent based thereon |
| 09/22/2011 | WO2011063178A3 Intravenous infusion of curcumin and a calcium channel blocker |
| 09/22/2011 | WO2011053792A3 Methods and compositions for sustained delivery of drugs |
| 09/22/2011 | WO2011044516A3 Compositions and methods comprising pediococcus for reducing at least one symptom associated with autism spectrum disease in a person diagnosed with an autism spectrum disease |
| 09/22/2011 | WO2011008274A3 Reduced volume formulation of glatiramer acetate and methods of administration |
| 09/22/2011 | WO2010053471A8 Modulators of atp-binding cassette transporters |
| 09/22/2011 | US20110230816 Gels for Transdermal Delivery |
| 09/22/2011 | US20110230568 Heating of polymers and other materials using radiation for drug delivery and other applications |
| 09/22/2011 | US20110230551 Withaferin a analogs and uses thereof |
| 09/22/2011 | US20110230549 Pharmaceutical compositions for the treatment of pain |
| 09/22/2011 | US20110230547 Potential Prognostic Markers and Therapeutic Targets for Neurological Disorders |
| 09/22/2011 | US20110230544 Modulation of c-reactive protein expression |
| 09/22/2011 | US20110230538 Pharmaceutical for use in the treatment of ureterolithiasis |
| 09/22/2011 | US20110230528 Use of Epothilone D in Treating Tau-Associated Diseases Including Alzheimer's Disease |
| 09/22/2011 | US20110230527 Caspase inhibitors and uses thereof |
| 09/22/2011 | US20110230526 Thiazolyl Mglur5 Antagonists and Methods for Their Use |
| 09/22/2011 | US20110230521 Pyrazole Compounds As CCR1 Antagonists |
| 09/22/2011 | US20110230519 Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| 09/22/2011 | US20110230514 Morphinan Compounds |
| 09/22/2011 | US20110230513 Pharmaceutical compositions for treatment of parkinsons disease |
| 09/22/2011 | US20110230512 Pharmaceutical Composition |
| 09/22/2011 | US20110230511 Carboxamide bioisosteres of opiates |
| 09/22/2011 | US20110230510 Pharmaceutical formulations containing opioid agonist, opioid antagonist and gelling agent |
| 09/22/2011 | US20110230505 Quinazoline inhibitors of bace 1 and methods of using |
| 09/22/2011 | US20110230504 ALLEVIATING DISORDERS WITH COMBINING AGENTS THAT INCREASE EPOXYGENATED FATTY ACIDS AND AGENTS THAT INCREASE cAMP |
| 09/22/2011 | US20110230497 Biologically active amides |
| 09/22/2011 | US20110230495 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds |
| 09/22/2011 | US20110230494 Heteroaryl compounds and uses thereof |
| 09/22/2011 | US20110230493 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors |
| 09/22/2011 | US20110230490 Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| 09/22/2011 | US20110230487 Arylsulfonamide ccr3 antagonists |
| 09/22/2011 | US20110230485 6-phenyl-pyrimidin-4-yl-(phenylamine or phenoxy) derivatives useful as modulators of nicotinic acetylcholine receptors |
| 09/22/2011 | US20110230484 Pyrazolyl-pyrimidine derivatives and their use as potassium channel modulators |
| 09/22/2011 | US20110230481 Derivatives of tetrabromobenzimidazole, a process for the preparation thereof, a pharmaceutical composition comprising the same, a method of using the same, a method for modulating or regulating serine/threonine kinases, and serine/threonine kinases modulating agent |
| 09/22/2011 | US20110230480 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders |
| 09/22/2011 | US20110230479 Neurotrophin mimetics and uses thereof |
| 09/22/2011 | US20110230473 Methods and Compositions for Treating Status Epilepticus and Seizures Causing Status Epilepticus |
| 09/22/2011 | US20110230469 Method to Determine the Risk for Side Effects of an SSRI Treatment in a Person |
| 09/22/2011 | US20110230464 Purine derivatives useful as p13 kinase inhibitors |
| 09/22/2011 | US20110230463 2h-chromene compound and derivative thereof |
| 09/22/2011 | US20110230462 Pyrrolopyrazine Kinase Inhibitors |
| 09/22/2011 | US20110230460 Thienotriazolodiazepine derivatives active on apo a |
| 09/22/2011 | US20110230459 Lactam acetamides as calcium channel blockers |
| 09/22/2011 | US20110230458 Phenyl-heteroaryl derivatives and methods of use thereof |
| 09/22/2011 | US20110230452 Compounds and methods for the treatment of pain and other diseases |
| 09/22/2011 | US20110230442 Na channels, disease, and related assays and compositions |
| 09/22/2011 | US20110230440 Inhibitors of fatty acid amide hydrolase |
| 09/22/2011 | US20110230428 Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| 09/22/2011 | US20110230415 Pharmaceutical Composition Containing GHRP-6 To Prevent And Eliminate Fibrosis And Other Pathological Deposits In Tissues |
| 09/22/2011 | US20110230414 Pyrrolopyrazine Kinase Inhibitors |
| 09/22/2011 | US20110230413 Predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| 09/22/2011 | US20110230407 Hepatocyte growth factor pathway activators in demyelinating diseases and central nervous system trauma |
| 09/22/2011 | US20110230392 Novel narc sc1, narc 10a, narc 1, narc 12, narc 13, narc17, narc 25, narc 3, narc 4, narc 7, narc 8, narc 11, narc 14a, narc 15, narc 16, narc 19, narc 20, narc 26, narc 27, narc 28, narc 30, narc 5, narc 6, narc 9, narc 10c, narc 8b, narc 9, narc2a, narc 16b, narc 1c, narc 1a, and narc 25 molecules and uses therefor |
| 09/22/2011 | US20110229944 FAD4, FAD5, FAD5-2, AND FAD6, Novel Fatty Acid Desaturase Family Members and Uses Thereof |
| 09/22/2011 | US20110229591 Withania somnifera plant extract and method of preparation thereof |
| 09/22/2011 | US20110229590 Pharmaceutical composition comprising ginger extract or shogaol |
| 09/22/2011 | US20110229578 Modafinil oral lyophilizate |
| 09/22/2011 | US20110229577 Biologically active silicic acid |
| 09/22/2011 | US20110229573 Process of manufacturing a lyophilized fast dissolving, multi-phasic dosage form |
| 09/22/2011 | US20110229570 Orally rapidly disintegrating tablet and process for producing same |
| 09/22/2011 | US20110229568 Michael systems as transglutaminase inhibitors |
| 09/22/2011 | US20110229566 Single Unit Oral Dose Pharmaceutical Composition Comprising Levodopa, Carbidopa And Entacapone Or Salts Thereof |